Biogen chops expenses in Q2, raises 2022 profit forecast
Cost cutting helped Biogen beat second-quarter expectations soundly even as revenue slid and sales of the drugmaker's controversial Alzheimer's treatment collapsed. Aduhelm, a drug…
Cost cutting helped Biogen beat second-quarter expectations soundly even as revenue slid and sales of the drugmaker's controversial Alzheimer's treatment collapsed. Aduhelm, a drug…